<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511731</url>
  </required_header>
  <id_info>
    <org_study_id>981325</org_study_id>
    <nct_id>NCT01511731</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions</brief_title>
  <official_title>Open-label, Randomized, 2-way Crossover Study to Compare the Bioavailability of Reddy Cheminor and Merck &amp;Co, Pepcid Famotidine Tablets 40 mg Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of Reddy
      Cheminor and Merck &amp;Co, pepcid 40 mg famotidine tablets under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description : The study was conducted as an open-label, randomized, single-dose,
      2-way crossover, relative bioavailability study performed on 30 healthy adult male
      volunteers. A total of 30 subjects completed the clinical phase of the study. Single oral 40
      mg doses were separated by a washout period of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">October 1998</completion_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose,0. 5, 1, 1. 33, 1. 67, 2, 2. 33, 2.67, 3, 3. 33, 3. 67, 4, 4. 5, 5, 6, 8, 10, 12, 16 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Famotidine tablets 40 mg of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pepcid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pepcid 40 mg Tablets of Merck &amp; Co.,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Famotidine Tablets 40 mg</description>
    <arm_group_label>Famotidine</arm_group_label>
    <other_name>Reddy Cheminor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pepcid</intervention_name>
    <description>40mg tablets</description>
    <arm_group_label>Pepcid</arm_group_label>
    <other_name>Merck &amp; Co.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

        History or presence of significant:

        â€¢ cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,
        immunologic, dermatologic, neurologic or psychiatric disease.

        In addition, history or presence of:

          -  alcoholism or drug abuse within the past year;

          -  hypersensitivity or idiosyncratic reaction to famotidine or any other histamine
             H2-receptor antagonist; Subjects who have been on an abnormal diet (for whatever
             reason) during the four weeks preceding the study.

        Subjects who, through completion of the study, would have donated in excess of:

          -  500 mL of blood in 14 days, or

          -  500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator),

          -  1000 mL of blood in 90 days,

          -  1250 mL of blood in 120 days,

          -  1500 mL of blood in 180 days,

          -  2000 mL of blood in 270 days,

          -  2500 mL of blood in 1 year. Subjects who have participated in another clinical trial
             within 28 days of study start.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Serfaty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Clinical Research Center</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>famotidine</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

